APRIL 2016 – The three drugmakers that dominate the world diabetes market—Indianapolis-based Eli Lilly and Co., Novo Nordisk A/S and Sanofi—are introducing improved forms of insulin, the sugar-regulating hormone some patients require, with a price tag to match. But with diabetes tearing across the developing world, health officials say the focus must return to meeting basic needs.

Click here to continue reading this article.